Leo Pharma
Leo Pharma, officially known as Leo Pharmaceutical Products Ltd., is a global leader in dermatology and critical care, headquartered in Denmark (DK). Founded in 1908, the company has established a strong presence in Europe, North America, and Asia, focusing on innovative solutions for skin diseases and conditions. With a commitment to research and development, Leo Pharma offers a range of unique products, including topical treatments and biologics, specifically designed for conditions such as psoriasis and eczema. The company is renowned for its patient-centric approach, ensuring that its therapies are both effective and accessible. As a prominent player in the pharmaceutical industry, Leo Pharma has achieved significant milestones, including numerous partnerships and advancements in dermatological care, solidifying its position as a trusted name in the market.
DitchCarbon Score
How does Leo Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Leo Pharma's score of 67 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Leo Pharma's reported carbon emissions
In 2024, LEO Pharma reported total carbon emissions of approximately 288,876,000 kg CO2e, with emissions distributed across various scopes: 20,050,000 kg CO2e from Scope 1, 266,000 kg CO2e from market-based Scope 2, and a significant 288,876,000 kg CO2e from Scope 3. The combined Scope 1 and 2 emissions amounted to about 22,316,000 kg CO2e. LEO Pharma has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 53% by 2030, using 2019 as the baseline year. This target aligns with the Science Based Targets initiative (SBTi) and is designed to support the global effort to limit temperature rise to 1.5°C. Additionally, the company plans for 75% of its suppliers, covering emissions from purchased goods and services, capital goods, and upstream transportation and distribution, to have science-based targets by 2026. In recent years, LEO Pharma has made progress towards its goals, with a reported reduction of approximately 39.2% in Scope 1 and 2 emissions by 2030 compared to 2019 levels. The company is actively working to enhance its sustainability practices and reduce its overall carbon footprint, reflecting a strong commitment to environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 12,395,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 10,100 | 00,000 | 00,000 | 00,000 | 00,000,000 | 0,000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 388,000 | 000,000 | 000,000 | 000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Leo Pharma is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
